SCHEMBL2011908

SCHEMBL2011908

COC(=O)C(C)N1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 1/20 0.49
CHRNB2 P17787 5/20 0.44
SLC6A2 P23975 5/20 0.44
CHRNB4 P30926 5/20 0.44
CHRNA3 P32297 5/20 0.44
CHRNA4 P43681 5/20 0.44
SLC6A3 Q01959 5/20 0.44
CHRNA1 P02708 4/20 0.44
CHRNG P07510 4/20 0.44
CHRNB1 P11230 4/20 0.44
CHRND Q07001 4/20 0.44
ATM Q13315 2/20 0.41
MAOB P27338 1/20 0.41
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10941017 1.00 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL5627160 0.98 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL11598889 0.89 RECQL (0.42) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL10088096 0.89 RECQL (0.42) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL23130574 0.83 KDM4E (0.44) ALDH1A1MEN1KMT2ALMNAATM
SCHEMBL20399152 0.81 KMT2A (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL20399168 0.81 KMT2A (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
Hydrochloric Acid SCHEMBL25423101 0.80 SIGMAR1 (0.43) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL28871477 0.79 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ALMNACHRNB2
SCHEMBL20868537 0.79 ALDH1A1 (0.46) ALDH1A1KMT2ALMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116507333-A Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use 上海睿跃生物科技有限公司 2023-07-28 CN disclosed
US-11673898-B2 Substituted inhibitors of menin-MLL and methods of use KURA ONCOLOGY, INC. (US) 2023-06-13 US disclosed
WO-2011073662-A1 COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2011-06-23 WO disclosed
CN-1183770-A Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation THOMAE GMBH DR K (DE) 1998-06-03 CN disclosed
US-5622681-A ION EXCHANGING HEAT STABLE SALT ANION WITH BASIC DIALYZING SOLUTION TO CONVERT TO HEAT REGENERABLE AMINE ABSORBENT; DONNAN EXCLUSION PRINCIPLES THE DOW CHEMICAL COMPANY (US) 1997-04-22 US disclosed
EP-0471592-B1 Process for absorption of sulfur compounds from fluids using certain piperidines, piperazines, or anhydrides of monocarboxylic amino acids DOW CHEMICAL CO (US) 1995-08-09 EP disclosed
US-5236678-A Process for absorption of sulfur compounds from fluids using piperidines THE DOW CHEMICAL COMPANY (US) 1993-08-17 US disclosed
EP-0552360-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-07-28 EP disclosed
WO-1993003825-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-03-04 WO disclosed
US-5167941-A Sulfur dioxide; cationic polyelectrolyte stabilizers THE DOW CHEMICAL COMPANY (US) 1992-12-01 US disclosed
US-5117055-A Method for direct conversion of fluorocarbonyl group into halogenides AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1992-05-26 US disclosed
EP-0471592-A2 Process for absorption of sulfur compounds from fluids using certain piperidines, piperazines, or anhydrides of monocarboxylic amino acids THE DOW CHEMICAL COMPANY (US) 1992-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673898-B2 Substituted inhibitors of menin-MLL and methods of use MLLT1, MEN1, MLLT3 ALDH1A1 4032/4885MEN1 2/4885KMT2A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.